What's new

Human medicines European public assessment report (EPAR): Lazcluze, lazertinib, Date of authorisation: 20/01/2025, Status: Authorised

Human medicines European public assessment report (EPAR): Lazcluze, lazertinib, Date of authorisation: 20/01/2025, Status: Authorised

Mar 17, 2025 - 16:54
 0
Human medicines European public assessment report (EPAR): Lazcluze, lazertinib, Date of authorisation: 20/01/2025, Status: Authorised
Human medicines European public assessment report (EPAR): Lazcluze, lazertinib, Date of authorisation: 20/01/2025, Status: Authorised
Read More

Tags:

Previous Article

Orca Bio to seek approval of T cell transplant after positive trial data

Next Article

Quest Nutrition debuts high-protein shake

Related Posts

Opinion/decision on a Paediatric investigation plan (PIP): Opsumit, Macitentan, decision type: PM: decision on the application for modification of an agreed PIP, therapeutic area: Cardiac disorders, PIP number: P/0457/2023

Opinion/decision on a Paediatric investigation plan (PI...

Mar 6, 2025  0

PSUSA/00010605/202407

PSUSA/00010605/202407

Feb 13, 2025  0

Meeting of the Medicine Shortages Single Point of Contact (SPOC) Working Party, Online, from 5 December 2024, 09:30 (CET) to 5 December 2024, 13:30 (CET)

Meeting of the Medicine Shortages Single Point of Conta...

Feb 10, 2025  0